Clinical Trial News and Research

RSS

Pervasis' PVS-30200 study data in prostate cancer presented at AACR meeting

Pervasis Therapeutics, Inc. today announced preclinical data showing positive effects of PVS-30200, the company's investigational cell therapy for the treatment of solid tumors, on controlling tumor growth and inhibiting metastases in an animal model of prostate cancer.

6 Apr 2011

Boston Scientific initiates clinical enrollment for INNOVA Self-Expanding Bare-Metal Stent System trial

Boston Scientific Corporation today announced the start of patient enrollment in the SuperNOVA clinical trial, an international, prospective, single-arm, non-randomized trial evaluating the safety and effectiveness of the INNOVA™ Self-Expanding Bare-Metal Stent System in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).

6 Apr 2011

FDA approves NeuroVasx cPAX Aneurysm Treatment System

NeuroVasx announced today that the FDA has approved the cPAX Aneurysm Treatment System as a Humanitarian Use Device for the treatment of large, giant and wide-neck cerebral aneurysms, which are typically the most difficult to treat. The HDE allows for the treatment of up to 4,000 patients per year in the U.S.

6 Apr 2011

Merck enters definitive agreement to acquire Inspire

Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products.

6 Apr 2011

MR patients treated with Abbott MitraClip system demonstrate clinical benefits of initial treatment at two years

Abbott today announced data from its EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) study showing that patients with significant mitral regurgitation (MR) treated with the company's investigational percutaneous catheter-based MitraClip® system continue to demonstrate the clinical benefits of initial treatment shown at one year out to two years, including improvements in heart function and reductions in symptoms.

5 Apr 2011

Less-invasive catheter-based aortic valve replacement as safe and effective as open surgery

Less-invasive catheter-based aortic valve replacement has a similar one-year survival as open valve-replacement surgery for patients at high risk for surgery.

5 Apr 2011

OncoGenex presents OGX-427 preclinical data in prostrate cancer at AACR meeting

OncoGenex Pharmaceuticals, Inc. announced today that preclinical data utilizing their pipeline compound OGX-427 was presented at the AACR 102nd Annual Meeting 2011.

5 Apr 2011

HCRI, MAHVI present transcatheter aortic valve data in severe stenosis at ACC meeting

The Harvard Clinical Research Institute and Saint Luke's Mid America Heart and Vascular Institute today announced that Matthew R. Reynolds, M.D., Director of the Economics and Quality of Life Research Center at HCRI, presented results of a cost-effectiveness analysis of transcatheter aortic valve replacement versus standard therapy for severe aortic stenosis, as part of the opening plenary session on April 3 at the American College of Cardiology 60th Annual Scientific Session & Expo.

5 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene,a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that new data from Phase 1 and 2 clinical studies of JX-594 were presented in an oral presentation at the 46th Annual Meeting of the European Association for the Study of the Liver over the weekend at the Internationales Congress Centrum in Berlin, Germany.

5 Apr 2011

Acamprosate can help treat patients with autism, Fragile X syndrome

In small, early clinical trials, adults and children with autism and Fragile X syndrome have shown improved communication and social behavior when treated with acamprosate, according to Craig Erickson, M.D., assistant professor of psychiatry at the Indiana University School of Medicine and chief of the Riley Hospital for Children Christian Sarkine Autism Treatment Center at Indiana University Health.

5 Apr 2011

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Idera Pharmaceuticals, Inc. today announced the presentation of data from its multiple-dose Phase 1 clinical trial of IMO-3100 in healthy subjects.

5 Apr 2011

Statins can help prevent risk of death from pneumonia

Taking statins could help prevent people dying from pneumonia, according to a study by the London School of Hygiene and Tropical Medicine.

5 Apr 2011

PLC's RenalGuard REMEDIAL II trial against CIN presented at ACC.11

PLC Systems Inc., a company focused on innovative medical device technologies, announced that final results from the REMEDIAL II investigator-sponsored clinical trial of RenalGuard in Italy were presented today.

5 Apr 2011

Positive outcomes from Medtronic's Resolute drug-eluting stent against coronary artery disease

Results of two major clinical studies presented at ACC.11 - the 60th Annual Scientific Session & Expo of the American College of Cardiology - demonstrate that the Resolute drug-eluting stent from Medtronic, Inc., provides a positive and persistent treatment effect for a wide variety of patients with coronary artery disease.

5 Apr 2011

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Viramune XR extended-release tablets, a one-pill, once-daily formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

5 Apr 2011

Cardioxyl's CXL-1020 preclinical data against heart failure presented at ACC meeting

Cardioxyl Pharmaceuticals, Inc. announced today that it is presenting two abstracts from studies of its lead clinical candidate, CXL-1020, at the American College of Cardiology's 60th Annual Scientific Session & Expo in New Orleans, Louisiana.

5 Apr 2011

Vermillion, Quest Diagnostics enter agreement to launch OVA1 IVDMIA assay in India

Vermillion, a molecular diagnostics company, today announced that it has signed an agreement with Quest Diagnostics to make OVA1 available in India. The companies are targeting a launch in the second quarter of 2011. Additionally, at the International Gynecologic Cancer Society (IGCS) regional meeting held in New Delhi April 2-3, 2011, Dr. Fred Ueland presented data demonstrating the high sensitivity for ovarian malignancy of OVA1 in combination with ultrasound.

From Quest Diagnostics 4 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon Inc. today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase, at the American Association of Cancer Research meeting in Orlando, Florida.

4 Apr 2011

Clinical Trial News and Research

Pervasis' PVS-30200 study data in prostate cancer presented at AACR meeting

Boston Scientific initiates clinical enrollment for INNOVA Self-Expanding Bare-Metal Stent System trial

FDA approves NeuroVasx cPAX Aneurysm Treatment System

Merck enters definitive agreement to acquire Inspire

MR patients treated with Abbott MitraClip system demonstrate clinical benefits of initial treatment at two years

Less-invasive catheter-based aortic valve replacement as safe and effective as open surgery

OncoGenex presents OGX-427 preclinical data in prostrate cancer at AACR meeting

HCRI, MAHVI present transcatheter aortic valve data in severe stenosis at ACC meeting

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

Acamprosate can help treat patients with autism, Fragile X syndrome

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Statins can help prevent risk of death from pneumonia

PLC's RenalGuard REMEDIAL II trial against CIN presented at ACC.11

Positive outcomes from Medtronic's Resolute drug-eluting stent against coronary artery disease

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Cardioxyl's CXL-1020 preclinical data against heart failure presented at ACC meeting

Vermillion, Quest Diagnostics enter agreement to launch OVA1 IVDMIA assay in India

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News